Ptc299 (DrugBank: PTC299)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 34 | 神経線維腫症 | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00911248 (ClinicalTrials.gov) | July 31, 2009 | 28/5/2009 | PTC299 for Treatment of Neurofibromatosis Type 2 | A Phase 2 Study to Assess the Efficacy, Safety, and Pharmacodynamic Activity of PTC299 in Patients With Neurofibromatosis Type 2 | Neurofibromatosis 2 | Drug: PTC299 | PTC Therapeutics | United States Department of Defense | Terminated | 18 Years | N/A | All | 11 | Phase 2 | United States |